Utility Scores for Risk-Reducing Mastectomy and Risk-Reducing Salpingo-Oophorectomy: Mapping to EQ-5D

Author:

Oxley Samuel G.12ORCID,Wei Xia13ORCID,Sideris Michail12ORCID,Blyuss Oleg14,Kalra Ashwin12,Sia Jacqueline J. Y.12,Ganesan Subhasheenee12,Fierheller Caitlin T.1,Sun Li3ORCID,Sadique Zia3ORCID,Jin Haomiao5ORCID,Manchanda Ranjit1236ORCID,Legood Rosa13ORCID

Affiliation:

1. Wolfson Institute of Population Health, Queen Mary University of London, London EC1M 6BQ, UK

2. Department of Gynaecological Oncology, Barts Health NHS Trust, Royal London Hospital, London E1 1BB, UK

3. Department of Health Services Research and Policy, London School of Hygiene & Tropical Medicine, London WC1H 9SH, UK

4. Department of Pediatrics and Pediatric Infectious Diseases, Institute of Child´s Health, Sechenov First Moscow State Medical University, Sechenov University, Moscow 119991, Russia

5. School of Health Sciences, Faculty of Health and Medical Sciences, University of Surrey, Guildford GU2 7YH, UK

6. MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, Faculty of Population Health Sciences, University College London, London WC1V 6LJ, UK

Abstract

Background: Risk-reducing mastectomy (RRM) and risk-reducing salpingo-oophorectomy (RRSO) are the most effective breast and ovarian cancer preventive interventions. EQ-5D is the recommended tool to assess the quality of life and determine health-related utility scores (HRUSs), yet there are no published EQ-5D HRUSs after these procedures. These are essential for clinicians counselling patients and for health-economic evaluations. Methods: We used aggregate data from our published systematic review and converted SF-36/SF-12 summary scores to EQ-5D HRUSs using a published mapping algorithm. Study control arm or age-matched country-specific reference values provided comparison. Random-effects meta-analysis provided adjusted disutilities and utility scores. Subgroup analyses included long-term vs. short-term follow-up. Results: Four studies (209 patients) reported RRM outcomes using SF-36, and five studies (742 patients) reported RRSO outcomes using SF-12/SF-36. RRM is associated with a long-term (>2 years) disutility of −0.08 (95% CI −0.11, −0.04) (I2 31.4%) and a utility of 0.92 (95% CI 0.88, 0.95) (I2 31.4%). RRSO is associated with a long-term (>1 year) disutility of −0.03 (95% CI −0.05, 0.00) (I2 17.2%) and a utility of 0.97 (95% CI 0.94, 0.99) (I2 34.0%). Conclusions: We present the first HRUSs sourced from patients following RRM and RRSO. There is a need for high-quality prospective studies to characterise quality of life at different timepoints.

Funder

Rosetrees Trust

Barts Charity

Publisher

MDPI AG

Reference62 articles.

1. Population-based genetic testing for cancer susceptibility genes: Quo vadis?;Manchanda;BJOG,2022

2. BRCA testing launched for people of Jewish ancestry in England;Venkatesan;Lancet Oncol.,2024

3. Carrier screening program for BRCA1/BRCA2 pathogenic variants among Ashkenazi Jewish women in Israel: An observational study;Greenberg;Genet. Med. Open,2023

4. NICE (2024, March 22). Ovarian Cancer: Identifying and Managing Familial and Genetic Risk. NICE Guideline [NG241]. Available online: https://www.nice.org.uk/guidance/ng241.

5. Current detection rates and time-to-detection of all identifiable BRCA carriers in the Greater London population;Manchanda;J. Med. Genet.,2018

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3